• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肢体I期恶性黑色素瘤(Clark分级IV/V级且厚度超过1.5毫米)患者区域灌注后的局部复发与生存情况

Local recurrence and survival in patients with (Clark Level IV/V and over 1.5-mm thickness) stage I malignant melanoma of the extremities after regional perfusion.

作者信息

Schraffordt Koops H, Beekhuis H, Oldhoff J, Oosterhuis J W, van der Ploeg E, Vermey A

出版信息

Cancer. 1981 Nov 1;48(9):1952-7. doi: 10.1002/1097-0142(19811101)48:9<1952::aid-cncr2820480907>3.0.co;2-x.

DOI:10.1002/1097-0142(19811101)48:9<1952::aid-cncr2820480907>3.0.co;2-x
PMID:7296506
Abstract

During the period 1965-1974, 110 patients with stage I malignant melanoma of the extremities were treated by regional isolated perfusion with L-phenylalanine mustard and local excision. In order to study local recurrence and survival, only patients with a primary melanoma Clark Level IV or V and a tumor thickness of more than 1.5 mm were accepted in this study. The determinate survival in patients followed for 5-14 years in 78%; 17% developed positive regional lymph nodes. The local skin recurrence rate was 9% (9 patients); four of these 9 patients simultaneously had distant metastases; the other five patients are alive with NED after retreatment. This series of patients, too, shows that tumor thickness determines the prognosis, both as to local recurrence and as to survival. The mean tumor thickness in the hyperthermically perfused patients was found to clearly exceed that in the normothermically perfused, the mean values being 4.85 mm and 3.87 mm, respectively. Yet local recurrence and regional lymph node metastases proved to be less frequent after hyperthermic than after normothermic perfusion, although the difference was not statistically significant.

摘要

1965年至1974年期间,110例肢体I期恶性黑色素瘤患者接受了左旋苯丙氨酸氮芥区域隔离灌注及局部切除治疗。为研究局部复发和生存率,本研究仅纳入原发性黑色素瘤为Clark IV级或V级且肿瘤厚度超过1.5 mm的患者。随访5至14年的患者中,确定生存率为78%;17%出现区域淋巴结阳性。局部皮肤复发率为9%(9例患者);这9例患者中有4例同时发生远处转移;另外5例患者经再次治疗后无疾病证据存活。该系列患者也表明,肿瘤厚度决定局部复发和生存率的预后。发现热灌注患者的平均肿瘤厚度明显超过常温灌注患者,平均值分别为4.85 mm和3.87 mm。然而,尽管差异无统计学意义,但热灌注后局部复发和区域淋巴结转移的发生率低于常温灌注。

相似文献

1
Local recurrence and survival in patients with (Clark Level IV/V and over 1.5-mm thickness) stage I malignant melanoma of the extremities after regional perfusion.肢体I期恶性黑色素瘤(Clark分级IV/V级且厚度超过1.5毫米)患者区域灌注后的局部复发与生存情况
Cancer. 1981 Nov 1;48(9):1952-7. doi: 10.1002/1097-0142(19811101)48:9<1952::aid-cncr2820480907>3.0.co;2-x.
2
[Regional perfusion treatment in primary malignant melanomas of the extremities. (Microstage IV/V according to Clark and tumor thickness over 1.5 mm)].[肢体原发性恶性黑色素瘤的区域灌注治疗。(根据克拉克分级为微分期IV/V且肿瘤厚度超过1.5毫米)]
Hautarzt. 1982 Sep;33(9):506-10.
3
Survival and regional disease control after isolation-perfusion for invasive stage I melanoma of the extremities.肢体侵袭性I期黑色素瘤隔离灌注后的生存情况及区域疾病控制
Cancer. 1976 Jan;37(1):188-98. doi: 10.1002/1097-0142(197601)37:1<188::aid-cncr2820370127>3.0.co;2-s.
4
Adjuvant regional isolated perfusion with melphalan for patients with Clark V melanoma of the extremities.美法仑辅助性区域隔离灌注治疗肢体克拉克V级黑色素瘤患者。
J Surg Oncol. 1993 Apr;52(4):249-54. doi: 10.1002/jso.2930520411.
5
Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs.预防性隔离灌注作为肢体侵袭性恶性黑色素瘤的主要治疗方法。
Ann Surg. 1975 Sep;182(3):316-24. doi: 10.1097/00000658-197509000-00014.
6
Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Wide surgical excision with and without adjuvant regional perfusion.两种治疗四肢原发性恶性黑色素瘤(Clark IV级和V级,厚度1.5毫米及以上)方法的比较。采用或不采用辅助区域灌注的广泛手术切除。
Cancer. 1986 May 15;57(10):1923-30. doi: 10.1002/1097-0142(19860515)57:10<1923::aid-cncr2820571006>3.0.co;2-e.
7
Regional isolated perfusion of extremities for melanoma: a 20-year experience with drugs other than L-phenylalanine mustard.肢体黑色素瘤的区域隔离灌注:20年使用除左旋苯丙氨酸氮芥之外其他药物的经验
Plast Reconstr Surg. 1997 Apr;99(4):1023-9. doi: 10.1097/00006534-199704000-00016.
8
[Preventive lymph node excision in the treatment concept of melanoma of the extremities].[预防性淋巴结切除在肢体黑色素瘤治疗理念中的应用]
Zentralbl Chir. 1996;121(6):474-7.
9
[Adjuvant regional isolation perfusion of the extremities of patients with stage I melanoma thicker than 1.5 mm].[对厚度超过1.5毫米的I期黑色素瘤患者肢体进行辅助性区域隔离灌注]
Ned Tijdschr Geneeskd. 1990 Oct 20;134(42):2042-7.
10
Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities.关于肢体I期黑色素瘤辅助性区域隔离灌注的争议。
World J Surg. 1992 Mar-Apr;16(2):241-5. doi: 10.1007/BF02071527.

引用本文的文献

1
The joints of the evolving foot. Part III. The fossil evidence.进化中足部的关节。第三部分。化石证据。
J Anat. 1980 Sep;131(Pt 2):275-98.
2
[Stroma-free hemoglobin solution and perfusion of isolated extremities].
Langenbecks Arch Chir. 1984;362(2):119-30. doi: 10.1007/BF01254186.
3
[Technic of isolated perfusion of the extremities. Experience with 171 cases].[肢体孤立灌注技术。171例经验]
Langenbecks Arch Chir. 1983;359(2):113-22. doi: 10.1007/BF01257258.
4
A prospective randomized study of regional extremity perfusion in patients with malignant melanoma.一项针对恶性黑色素瘤患者肢体区域灌注的前瞻性随机研究。
Ann Surg. 1984 Dec;200(6):764-8. doi: 10.1097/00000658-198412000-00016.
5
Isolated regional perfusion in malignant melanoma of the extremities.肢体恶性黑色素瘤的孤立区域灌注。
World J Surg. 1987 Aug;11(4):527-33. doi: 10.1007/BF01655819.
6
Hyperthermic perfusion with chemotherapy for melanoma of the extremities.肢体黑色素瘤的热灌注化疗
World J Surg. 1989 Sep-Oct;13(5):598-602. doi: 10.1007/BF01658878.
7
The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.美法仑隔离肢体灌注治疗恶性黑色素瘤的药代动力学优势。
Br J Cancer. 1992 Jul;66(1):159-66. doi: 10.1038/bjc.1992.235.
8
Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities.关于肢体I期黑色素瘤辅助性区域隔离灌注的争议。
World J Surg. 1992 Mar-Apr;16(2):241-5. doi: 10.1007/BF02071527.